TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11243947
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily)
Study: 9645184
Drug: Levothyroxine in
Normalized name: levothyroxine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine in a weight‐adapted dosage (75, 100 or 150 micrograms) plus 150 micrograms iodide
Study: 3064775
Drug: Radiotherapy +
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy + tamoxifen (TAM), 30 mg daily for 1 year
Study: 31451364
Drug: Tablet-based PAINUCope
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based PAINUCope intervention focused on barriers to pain management, pain, and analgesic adherence
Study: 23991896
Drug: subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous immunotherapy with mixed depigmented‐polymerized birch and grass pollen extract
Study: 15493172
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy for twelve cytology-negative patients (control group)
Study: 11550726
Drug: Increased therapist
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased therapist self-disclosure during treatment
Study: 11550726
Drug: No therapist
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapist self-disclosure during treatment
Study: 24260825
Drug: Nitazoxanide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (100 mg and 200 mg every 12 hours for 3 days)
Study: 20374563
Drug: Continuous antiretroviral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous antiretroviral therapy (C-ART)
Study: 8408738
Drug: Propranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20 mg)
Study: 3933067
Drug: Mepindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepindolol (5 mg)
Study: 3933067
Drug: Salbutamol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (20 mg)
Study: 30055046
Drug: Samidorphan 1
Normalized name: samidorphan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samidorphan 1 mg/d
Study: 30055046
Drug: Samidorphan 10
Normalized name: samidorphan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samidorphan 10 mg/d
Study: 27030279
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab treatment
Study: 15897845
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral rofecoxib
Study: 11016665
Drug: Barrier creams
Normalized name: Valiant Barrier
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier creams (3 representative commercial barrier creams)
Study: 11016665
Drug: Control skin
Normalized name: ALLANTOIN 5 mg in 1 mL TOPICAL GEL [SkinCeuticals Advanced Scar Control Skin Protectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control skin (no barrier cream used)
Study: 1620139
Drug: Physostigmine (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (0.02 mg/kg)
Study: 6137231
Drug: Atropine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.04 mg/kg)
Study: 6151914
Drug: Oxatomide 30
Normalized name: oxatomide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide 30 mg b.i.d. for 2 months
Study: 30661474
Drug: 1000 mg/d
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/d sodium diet
Study: 29278529
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL sodium chloride 0.9 (placebo)
Study: 27270263
Drug: L‐thyroxine replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐thyroxine replacement therapy
Study: 24610399
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) and quitline referral (Group MNQ)
Study: 24610399
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) and quitline referral (Group UNQ)
Study: 19811890
Drug: Coordination therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coordination therapy (CTh)
Study: 15882280
Drug: Systemic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic heparin anticoagulation
Study: 7995617
Drug: Continuous plus
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous plus pulsatile overnight GH administration (50% constant delivery + 3 pulses)
Study: 7995617
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily injection of GH
Study: 3593904
Drug: Flurbiprofen (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (oral doses)
Study: 26653112
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU daily vitamin D3
Study: 26562709
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein (12 g protein, 7 g essential amino acids)
Study: 26562709
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (12 g protein, 7 g essential amino acids)
Study: 26562709
Drug: Rice milk
Normalized name: NIACINAMIDE 80 mg in 1 g / CAFFEINE 30 mg in 1 g / HYALURONIC ACID 60 mg in 1 g / PANAX GINSENG ROOT OIL 80 mg in 1 g TOPICAL CREAM [MOISTURIZING Soothing Eye Cream with aloe and rice milk]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice milk (nonprotein control, 12 g protein, 7 g essential amino acids)
Study: 19560838
Drug: 1+1 hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1+1 hydromorphone patient‐driven protocol (1 mg IV hydromorphone followed by a second 1‐mg dose 15 minutes later if requested)
Study: 19560838
Drug: Traditional physician‐driven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physician‐driven administration of opioids (any IV opioid at the discretion of the attending physician)
Study: 19560838
Drug: 1+1 hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1+1 hydromorphone patient‐driven protocol and Traditional physician‐driven administration
Study: 6373344
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (50 mg b.d. for the first three months, with possible increase of 50 mg after the third and/or sixth month if PaO2 increase is less than 5 mmHg and well tolerated)
Study: 30286303
Drug: Fortified milk
Normalized name: Fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified milk (200 mL daily, enriched with 3 μg of vitamin D3)
Study: 30286303
Drug: Nonfortified milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonfortified milk (200 mL daily, natural abundance of vitamin D3, about 1.5 μg)
Study: 16755554
Drug: Pramipexole (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.125 to 0.75 mg/day)
Study: 30768684
Drug: Oral briefing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral briefing followed by a 4-min planning discussion
Study: 20621734
Drug: Erlotinib (EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (EGFR tyrosine kinase inhibitor)
Study: 16996172
Drug: Peru-15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-15 vaccine (2x10^8 cfu)
Study: 16996172
Drug: Peru-15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-15 vaccine (2x10^7 cfu)
Study: 16358380
Drug: Low-dosage levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage levothyroxine (L-T4) at an initial dosage of 3.21-5.81 microg/(kg.d), average of 16.25±3.87 microg/d, for a mean duration of therapy of 28.09±9.56 months.
Study: 11528582
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg/week)
Study: 9780524
Drug: Direct hypnotic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct hypnotic suggestions (Harvard Group Scale of Hypnotizability)
Study: 9780524
Drug: Indirect hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indirect hypnotic suggestions (Alman Wexler Indirect Hypnotic Susceptibility Scale)
Study: 3215160
Drug: Weight gain
Normalized name: Nutritional Supplement Oral Powder for Suspension [MUSCLE & WEIGHT GAINER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight gain prevention treatment (monthly newsletters, financial incentives, optional education course)
Study: 26200520
Drug: Participant characteristics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant characteristics (marital status, use of sleep medication, comorbidity, posttraumatic stress disorder, living arrangement)
Study: 20938664
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg/month
Study: 16798391
Drug: Dihydroartemisinin-piperaquine (6.3/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (6.3/50 mg/kg)
Study: 16798391
Drug: Artesunate-mefloquine (12/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-mefloquine (12/25 mg/kg)
Study: 12824948
Drug: Aspirin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (80 mg per day)
Study: 11070146
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1.5 g)
Study: 11070146
Drug: Sesame oil
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesame oil (4.5 g)
Study: 12955426
Drug: Heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin therapy alone
Study: 25431225
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen Dripping Pills
Study: 30741894
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (steroids and diuretics simultaneously for 2 weeks)
Study: 30741894
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (diuretics for 2 weeks followed by steroids for another 2 weeks if no response)
Study: 1150903
Drug: Indomethacin administered
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin administered concurrently with warfarin for five days
Study: 1150903
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of warfarin administered before and after ten consecutive days of oral indomethacin administration
Study: 17916877
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide intravenous bolus infusion over 2 min (BIG group)
Study: 9619011
Drug: Intermittent perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent perfusion of cold crystalloid (St. Thomas Hospital solution) with hypothermic CPB
Study: 16229019
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg b.i.d.
Study: 7713856
Drug: Biperiden 2
Normalized name: biperiden 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden 2 mg b.i.d.
Study: 2502974
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid rectal suppository (500 mg)
Study: 2502974
Drug: Oral valproate
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral valproate sodium syrup (500 mg)
Study: 9629401
Drug: Propranolol 60
Normalized name: propranolol 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 60 mg/day
Study: 30431297
Drug: Practice of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice of therapy-acquired regulatory skills
Study: 23746555
Drug: Liraglutide 1.8mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8mg added to metformin followed by insulin detemir for 52 weeks (RT group)
Study: 19927363
Drug: Immunosuppressive drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive drug therapy (IDT) only
Study: 8077353
Drug: Evening calcium
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening calcium supplementation (1000 mg for 14 days)
Study: 8077353
Drug: Morning calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning calcium supplementation (1000 mg for 14 days)
Study: 2807562
Drug: Enoxacin 400
Normalized name: enoxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 400 mg administered one hour before ESWL
Study: 7224261
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (control group)
Study: 31609396
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to another SSRI or to venlafaxine with cognitive behavioral therapy
Study: 31609396
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to another SSRI or to venlafaxine without cognitive behavioral therapy
Study: 23290112
Drug: 3-month neoadjuvant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month neoadjuvant hormonal therapy (NHT) before (125)I permanent seed implantation
Study: 17579840
Drug: ropinirole 0.5
Normalized name: ropinirole 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropinirole 0.5 mg
Study: 17579840
Drug: ropinirole 0.25
Normalized name: ropinirole 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropinirole 0.25 mg
Study: 15956965
Drug: ZD4054 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD4054 (single oral dose)
Study: 15956965
Drug: ZD4054 (ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD4054 (ascending single-dose)
Study: 7437242
Drug: Indacrinone (MK-196)
Normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indacrinone (MK-196) 60 mg
Study: 7437242
Drug: Indacrinone (MK-196)
Normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indacrinone (MK-196) 40 mg
Study: 22198243
Drug: CA-125 velocity
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA-125 velocity (average velocity of 19.749 U/ml per month)
Study: 22198243
Drug: Non-cancer group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-cancer group (average velocity of 0.035 U/ml per month)
Study: 17889549
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and Maxillofacial Surgery (OMFS) patients
Study: 17889549
Drug: Control groups
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control groups (surgical, dental, and general practitioners/internal medicine patients)
Study: 6773613
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg/day
Study: 10670264
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg subarachnoid morphine with bupivacaine (group M)
Study: 6885575
Drug: Respiratory acidosis
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory acidosis (induced by 5% CO2 inhalation)
Study: 24735128
Drug: 360 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 μg budesonide
Study: 24735128
Drug: 720 μg
Normalized name: POLICRESULEN 720 mg in 1 g ORAL LIQUID [ALBOTHYL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720 μg budesonide
Study: 24735128
Drug: 1,440 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,440 μg budesonide
Study: 24735128
Drug: four repetitive
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: four repetitive 720-μg budesonide doses
Study: 20819220
Drug: Carbon ion
Normalized name: CARBON ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon ion boost applied to the macroscopic tumor up to a total dose of 18 Gy E in 6 fractions at a single dose of 3 Gy E.
Study: 20819220
Drug: Proton boost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton boost applied up to a total dose of 10 Gy E in 5 single fractions of 2 Gy E.
Study: 9032748
Drug: Low-dose estrogens
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estrogens (0.625 mg of conjugated estrogens)
Study: 3719163
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ultrasound treatment
Study: 30784667
Drug: Long-term dual
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term dual antiplatelet therapy (DAPT)
Study: 16169093
Drug: Intranasal mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal mometasone furoate monohydrate 100 mcg/day
Study: 15202297
Drug: ACE inhibitors,
Normalized name: ACE INHIBITORS, PLAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors, beta-blockers, and aldosterone antagonists (combined therapy)
Study: 15202297
Drug: ACE inhibitors,
Normalized name: ACE INHIBITORS, PLAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors, beta-blockers, and aldosterone antagonists (individual drugs)
Study: 9241006
Drug: Gepirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone (10 to 45 mg daily)
Study: 9241006
Drug: Diazepam (19.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (19.5 +/- 12.5 mg/day)
Study: 8309606
Drug: e.v. immunoglobulins
Approvals — FDA: no, EMA: no, PMDA: no
Description: e.v. immunoglobulins associated with routine antibiotic prophylaxis
Study: 2894903
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: tubocurarine (DTC) 3 mg + succinylcholine 1.5 mg.kg‐1
Study: 2894903
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: atracurium 0.05 mg.kg‐1 + 0.35 mg.kg‐1
Study: 2894903
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: vecuronium 0.1 mg.kg‐1 as a single bolus
Study: 3299182
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 supplementation (150 mg daily)
Study: 30223083
Drug: liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.8 mg/day
Study: 24283110
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg (n=98)
Study: 21275437
Drug: Clopidogrel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel therapy (600 mg loading dose and 75 mg/day maintenance dose) plus aspirin (300 mg/day)
Study: 17952589
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg PO daily)
Study: 17952589
Drug: Exemestane (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25 mg PO daily)
Study: 17952589
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Raloxifene 60 mg PO daily + Exemestane 25 mg PO daily)
Study: 1289019
Drug: Bedtime insulin
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime insulin (BTI)
Study: 1289019
Drug: Morning insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning insulin (MI)
Study: 3881323
Drug: d-penicillamine 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-penicillamine 1200 mg daily
Study: 31208475
Drug: Sour cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sour cream
Study: 19555253
Drug: Fenofibrate 145
Normalized name: fenofibrate 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 145 mg/day
Study: 2586204
Drug: Xipamide 20
Normalized name: xipamide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xipamide 20 mg once a day for 16 weeks
Study: 1100213
Drug: Alpha methyldopahydrazine
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha methyldopahydrazine in combination with L-dopa
Study: 1100213
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with L-dopa
Study: 18648199
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day for 3 months
Study: 18758373
Drug: Immediate-release omeprazole
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release omeprazole 40 mg
Study: 20823079
Drug: Scopolamine bromide
Normalized name: Methscopolamine Bromide
DrugBank: Methscopolamine bromide (DB00462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine bromide (0.4 mg i.m.)
Study: 17388713
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg/day increased to 20 mg/day after week 4)
Study: 17388713
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after tapering from escitalopram)
Study: 14696230
Drug: OptiMARK (gadoversetamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: OptiMARK (gadoversetamide injection) administered via power injector
Study: 11177120
Drug: Organized depression
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organized depression management program including patient education, antidepressant pharmacotherapy, systematic telephone monitoring, and psychiatric consultation.
Study: 11177120
Drug: Total health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Family Wellness Total Health]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total health services costs (including health services and time-in-treatment costs).
Study: 11177120
Drug: Health services
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health services plus time-in-treatment costs.
Study: 11177120
Drug: Total health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Family Wellness Total Health]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total health services and time-in-treatment costs.
Study: 3168573
Drug: Isoetharine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoetharine, 1 percent solution
Study: 29197931
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lower-limb compression therapy)
Study: 27469583
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (1500 mg twice daily for 24 months)